{
    "clinical_study": {
        "@rank": "18415", 
        "arm_group": {
            "arm_group_label": "Dose Escalation of Panobinostat, Plus Ipilimumab", 
            "arm_group_type": "Experimental", 
            "description": "Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg) along with a dose of ipilimumab of 3 mg per kg (mg/kg) of body weight."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out if an investigational drug called panobinostat can\n      be given safely with another drug called ipilimumab. Investigators want to learn more about\n      the side effects of this combination of drugs using different doses of panobinostat and the\n      same dose of ipilimumab."
        }, 
        "brief_title": "Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Melanoma", 
            "Skin Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Skin Neoplasms", 
                "Melanoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women \u2265 18 years old\n\n          -  Participants must be ipilimumab na\u00efve with progressive unresectable Stage III or\n             Stage IV melanoma who are either treatment na\u00efve or may have been treated with up to\n             3 prior treatments for melanoma (e.g., chemotherapy, biologic or targeted therapy or\n             IL-2).\n\n          -  Histologic or cytologic confirmation of stage III or stage IV melanoma\n\n          -  Measurable disease at baseline as assessed by CT and/or MRI\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n          -  Screening laboratory values must meet the following criteria: white blood count\n             (WBCs) \u2265 2000/\u03bcL; Neutrophils \u2265 1500/\u03bcL; Platelets \u2265 100 x 10^3/\u03bcL; Hemoglobin \u2265 9.0\n             g/dL; Creatinine Serum creatinine \u2264 1.5 x upper limit of normal (ULN) or creatinine\n             clearance > 40 mL/minute (using Cockcroft/Gault formula); aspartic transaminase (AST)\n             \u2264 3 x ULN; alanine transaminase (ALT) \u2264 3 x ULN; Total Bilirubin \u2264 1.5 x ULN (except\n             those with Gilbert Syndrome who must have total bilirubin < 3.0 mg/dL)\n\n          -  Men and women of childbearing potential (WOCBP) must be using an acceptable method of\n             contraception to avoid pregnancy throughout the study and for at least 12 weeks after\n             the last dose of investigational product in such a manner that the risk of pregnancy\n             is minimized. Women must have a negative serum pregnancy test within 72 hours prior\n             to the start of investigational product.\n\n        Exclusion Criteria:\n\n          -  Known or suspected brain metastasis, or brain as the only site of disease, with the\n             following exceptions: controlled brain metastasis (no radiographic progression at\n             least 4 weeks following radiation and/or surgical treatment, off steroids for at\n             least 4 weeks, and have no new or progressing neurological signs or symptoms);\n             history of prior malignancy with the exception of carcinoma in situ of the cervix or\n             other malignancy diagnosed > 2 years ago that has undergone potentially curative\n             therapy with no evidence of disease for the last \u2265 2 years and that is deemed by the\n             investigator to be at a low risk of recurrence\n\n          -  Active autoimmune disease or a history of known or suspected autoimmune disease with\n             the exception of subjects with isolated vitiligo, treated thyroiditis or resolved\n             childhood asthma/atopy\n\n          -  Known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C\n             infection\n\n          -  History of any hepatitis (e.g., alcohol or non-alcohol steatohepatitis (NASH), drug-\n             related, autoimmune)\n\n          -  Evidence of active infection that requires anti-bacterial, anti-viral, or anti-fungal\n             therapy \u2264 7 days prior to initiation of study drug therapy\n\n          -  History of acute diverticulitis, or current chronic diarrhea\n\n          -  Active peptic ulcer disease even if asymptomatic\n\n          -  History of adrenal insufficiency (including subjects using replacement therapy)\n\n          -  Prior organ allograft or allogeneic bone marrow transplantation\n\n          -  Uncontrolled or significant cardiovascular disease including, but not limited to, any\n             of the following: Myocardial infarction within the past 6 months; Uncontrolled angina\n             within the past 6 months; Any history of clinically significant ventricular\n             arrhythmias (such as ventricular tachycardia, ventricular fibrillation or Torsades de\n             pointes). Controlled atrial fibrillation by itself is not an exclusion criterion.;\n             Baseline corrected QT interval (QTc) interval greater than 500 milliseconds\n\n          -  Baseline toxicities from prior anti-cancer treatments > Grade 1\n\n          -  Inability to be venipunctured and/or tolerate venous access\n\n          -  Any major surgery within 4 weeks or a diagnostic procedure (e.g. incision, needle\n             biopsy) within 1 day of study drug administration\n\n          -  Any current or recent (within 3 months) gastrointestinal disease that could\n             potentially impact the ability to swallow and/or absorb study drug (i.e.,\n             gastrointestinal surgery, malabsorption syndrome)\n\n          -  Diabetes mellitus uncontrolled by medication\n\n          -  Known drug or alcohol abuse\n\n          -  Presence of underlying medical condition that in the opinion of the Investigator or\n             Sponsor could adversely affect the ability of the subject to comply with or tolerate\n             study procedures and/or study therapy, or confound the ability to interpret the\n             tolerability of combined administration of panobinostat and ipilimumab in treated\n             subjects\n\n          -  History of allergy to components of ipilimumab or panobinostat, or known allergy to\n             other antibody therapies.\n\n          -  WOCBP who are unwilling or unable to use an acceptable method to minimize the risk of\n             pregnancy for the entire study period and for at least 12 weeks after the last dose\n             of investigational product\n\n          -  Women who are pregnant or breastfeeding\n\n          -  Women with a positive pregnancy test on enrollment or prior to investigational\n             product administration\n\n          -  Sexually active fertile men not using effective birth control if their partners are\n             WOCBP\n\n          -  Exposure to any investigational drug within 4 weeks of study drug administration.\n\n          -  Any anti-cancer therapy (e.g., chemotherapy, biologics, radiotherapy, or hormonal\n             treatment) within 4 weeks or at least 5 half-lives (whichever is longer) of study\n             drug administration\n\n          -  Prior therapy with an anti-CTLA4 antibody or an HDAC inhibitor\n\n          -  Concurrent chemotherapy, hormonal therapy, immunotherapy regimens, or radiation\n             therapy, standard or investigational\n\n          -  Prisoners or subjects who are involuntarily incarcerated\n\n          -  Subjects who are compulsorily detained for treatment of either a psychiatric or\n             physical (e.g., infectious disease) illness"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032810", 
            "org_study_id": "MCC-17439"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dose Escalation of Panobinostat, Plus Ipilimumab", 
                "description": "Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.", 
                "intervention_name": "Panobinostat", 
                "intervention_type": "Drug", 
                "other_name": "LBH 589"
            }, 
            {
                "arm_group_label": "Dose Escalation of Panobinostat, Plus Ipilimumab", 
                "description": "Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Drug", 
                "other_name": "BMS-734016"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Histone Deacetylase Inhibitors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Stage III Melanoma", 
            "Stage IV Melanoma", 
            "HDAC Inhibitor"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "link": {
            "description": "Moffitt Cancer Center Clinical Trials website", 
            "url": "http://www.moffitt.org/research--clinical-trials/clinical-trials"
        }, 
        "location": {
            "contact": {
                "email": "stephanie.merek@moffitt.org", 
                "last_name": "Stephanie Merek", 
                "phone": "813-745-4858"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Jeffrey Weber, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Geoffrey Gibney, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ragini Kudchadkar, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amod Sarnaik, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jonathan Zager, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Jeffrey Weber, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of panobinostat administered in combination with ipilimumab in participants with unresectable Stage III or Stage IV melanoma.\nThe trial will enroll up to 36 patients for determination of the MTD, but will be successfully concluded earlier if 12 patients are accrued at the dose determined to be the MTD, with 3 dose limiting toxicities (DLTs).\nAll participants who receive study any drug therapy will be evaluated for safety. Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests. Triplicate 12-lead electrocardiograms (ECGs) will be collected prior to dosing on Day 1 of induction cycle 1. Single 12-lead ECGs will be collected at screening, prior to dosing on Day 1 of each treatment cycle, at the end of treatment and at the 90-day follow up visit.", 
            "measure": "Maximum Tolerated Dose (MTD)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032810"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related Response Criteria (irRC).\nRECIST:  Best overall response from start of treatment until disease progression/recurrence.  Progressive Disease (PD) = 20% increase in the sum of the longest diameter of target lesions.\nImmune-related Complete Response (irCR): Complete disappearance of all tumor lesions for at least 4 weeks from date of documentation of irCR.  Immune-related Partial Response (irPR): Sum of the products of the 2 largest perpendicular diameters of all index lesions, measured and captured as the Sum of Product of Diameters (SPD) baseline.  Immune-related Progressive Disease (irPD): At least a 25% increase in the SPD of all index lesions and new measurable lesions (irSPD) over the nadir SPD calculated for the index lesions.", 
            "measure": "Occurrence of Anti-tumor Activity of Panobinostat Administered in Combination with Ipilimumab", 
            "safety_issue": "No", 
            "time_frame": "Up to 36 months"
        }, 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}